Mirae Asset Global Investments Co., Ltd. Cullinan Oncology, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,280 shares of CGEM stock, worth $19,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,280
Previous 1,974
15.5%
Holding current value
$19,676
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$66 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.6 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$38 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33.3 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.6 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $394M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...